Humana Inc. (NYSE: HUM) has a higher price-to-earnings ratio of 27.05x compared to its average ratio. HUM has 36-month beta value of 0.50. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 7 as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for HUM is 120.10M, and currently, short sellers hold a 1.87% ratio of that float. The average trading volume of HUM on September 04, 2024 was 1.16M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
HUM) stock’s latest price update
The stock of Humana Inc. (NYSE: HUM) has increased by 4.39 when compared to last closing price of 363.53. Despite this, the company has experienced a 7.36% gain in its stock price over the last five trading sessions. zacks.com reported 2024-08-30 that HUM collaborates with Evergreen Nephrology to introduce a specialized care program for chronic kidney disease patients.
HUM’s Market Performance
Humana Inc. (HUM) has seen a 7.36% rise in stock performance for the week, with a 6.51% gain in the past month and a 5.16% surge in the past quarter. The volatility ratio for the week is 1.85%, and the volatility levels for the past 30 days are at 1.94% for HUM. The simple moving average for the past 20 days is 7.26% for HUM’s stock, with a -0.03% simple moving average for the past 200 days.
Analysts’ Opinion of HUM
Many brokerage firms have already submitted their reports for HUM stocks, with Piper Sandler repeating the rating for HUM by listing it as a “Overweight.” The predicted price for HUM in the upcoming period, according to Piper Sandler is $392 based on the research report published on June 26, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see HUM reach a price target of $374. The rating they have provided for HUM stocks is “Equal-Weight” according to the report published on June 24th, 2024.
BofA Securities gave a rating of “Neutral” to HUM, setting the target price at $342 in the report published on April 02nd of the current year.
HUM Trading at 3.21% from the 50-Day Moving Average
After a stumble in the market that brought HUM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.47% of loss for the given period.
Volatility was left at 1.94%, however, over the last 30 days, the volatility rate increased by 1.85%, as shares surge +7.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.49% upper at present.
During the last 5 trading sessions, HUM rose by +7.88%, which changed the moving average for the period of 200-days by -24.76% in comparison to the 20-day moving average, which settled at $355.09. In addition, Humana Inc. saw -17.11% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HUM starting from Mesquita Jorge S., who purchase 545 shares at the price of $367.09 back on Feb 20 ’24. After this action, Mesquita Jorge S. now owns 2,578 shares of Humana Inc., valued at $200,066 using the latest closing price.
Stock Fundamentals for HUM
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.88 for the gross margin
The net margin for Humana Inc. stands at 0.02. The total capital return value is set at 0.1. Equity return is now at value 10.21, with 3.21 for asset returns.
Based on Humana Inc. (HUM), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at -0.33. The debt to equity ratio resting at 0.77. The interest coverage ratio of the stock is 5.26.
Currently, EBITDA for the company is 4.73 billion with net debt to EBITDA at 3.23. When we switch over and look at the enterprise to sales, we see a ratio of 0.47. The receivables turnover for the company is 27.39for trailing twelve months and the total asset turnover is 2.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.66.
Conclusion
To put it simply, Humana Inc. (HUM) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
